PAMU
SRPT icon

Pictet Asset Management (UK)’s Sarepta Therapeutics SRPT Stock Holding History

Pictet Asset Management (UK)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$26.2M Buy
336,845
+54,760
+19% +$4.15M 0.03% 468
2021
Q1 		$21M Sell
282,085
-201,227
-42% -$18.6M 0.03% 488
2020
Q4 		$82.4M Sell
483,312
-40,987
-8% -$6.07M 0.11% 233
2020
Q3 		$73.6M Sell
524,299
-189,221
-27% -$28.8M 0.12% 212
2020
Q2 		$114M Buy
713,520
+209,226
+41% +$28.5M 0.2% 152
2020
Q1 		$49.3M Sell
504,294
-3,085
-0.6% -$353K 0.11% 223
2019
Q4 		$65.5M Sell
507,379
-171,472
-25% -$17.3M 0.12% 219
2019
Q3 		$51.1M Buy
678,851
+220,668
+48% +$26.1M 0.11% 221
2019
Q2 		$69.6M Buy
458,183
+189,628
+71% +$23M 0.15% 180
2019
Q1 		$32M Buy
268,555
+2,423
+0.9% +$312K 0.07% 310
2018
Q4 		$29K Sell
266,132
-4,923
-2% -$616K 0.07% 310
2018
Q3 		$43.8M Sell
271,055
-45,284
-14% -$6.19M 0.09% 264
2018
Q2 		$41.8M Sell
316,339
-184,567
-37% -$17.4M 0.1% 254
2018
Q1 		$37.1M Buy
500,906
+460,706
+1,146% +$30.7M 0.09% 278
2017
Q4 		$2.24M Buy
40,200
+3,800
+10% +$201K 0.01% 792
2017
Q3 		$1.65M Sell
36,400
-34,700
-49% -$1.39M ﹤0.01% 804
2017
Q2 		$2.12M Buy
71,100
+3,500
+5% +$114K 0.01% 777
2017
Q1 		$2M Buy
67,600
+13,400
+25% +$415K 0.01% 773
2016
Q4 		$1.49M Buy
+54,200
New +$2.18M 0.01% 780
2015
Q4 		– Sell
-18,900
Closed -$607K – 868
2015
Q3 		$607K Buy
+18,900
New +$641K ﹤0.01% 818

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Pictet Asset Management (UK)'s SRPT Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Sarepta Therapeutics (SRPT) stake by 19% in Q2 2021, buying an estimated $4.15M and bringing the position to 336,845 shares worth $26.2M. The position accounts for 0.03% of the portfolio, ranked #468.

Pictet Asset Management (UK) first reported a position in SRPT in Q3 2015 and has held it in 20 quarters since. The position peaked at $114M in Q2 2020. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • Pictet Asset Management (UK) held 336,845 shares of Sarepta Therapeutics worth $26.2M as of Q2 2021.
  • Pictet Asset Management (UK) bought 54,760 Sarepta Therapeutics shares in Q2 2021, an estimated $4.15M.
  • Sarepta Therapeutics made up 0.03% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #468 holding.
  • Pictet Asset Management (UK) first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 20 quarters since.
  • Pictet Asset Management (UK)'s Sarepta Therapeutics position peaked at $114M in Q2 2020.
  • 331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.